GlassScriptPhysician profile
Cathy Dionisio
NPI 1407220221
$5,031.24
in general payments reported to CMS, 2019-2025
50 companies · $786 in 2025
The $786 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $597 · 2022: $1,052 · 2023: $1,236 · 2024: $1,360 · 2025: $786.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,202 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,201.56 |
| Education | $180.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $604.21 | 2022-2025 | |
| Lilly USA, LLC | $422.30 | 2021-2023 | Jaypirca, Verzenio, Retevmo |
| Astrazeneca Pharmaceuticals LP | $402.41 | 2021-2025 | Tagrisso |
| Incyte Corporation | $399.81 | 2021-2025 | Jakafi, Monjuvi, Pemazyre |
| Merck Sharp & Dohme LLC | $340.74 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $340.14 | 2022-2025 | |
| Abbvie INC. | $238.86 | 2022-2025 | |
| Celgene Corporation | $164.50 | 2021-2024 | Reblozyl |
| Astellas Pharma US INC | $146.58 | 2021-2024 | Xtandi |
| Janssen Biotech, INC. | $145.32 | 2021-2025 | Imbruvica, Erleada, Akeega |
| Daiichi Sankyo INC. | $135.17 | 2021-2025 | Enhertu, Injectafer |
| Genzyme Corporation | $131.28 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $125.83 | 2021-2023 | |
| Sobi, INC | $124.77 | 2022 | |
| Jazz Pharmaceuticals INC. | $107.47 | 2022-2025 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cathy Dionisio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.